PER 2.35% 8.7¢ percheron therapeutics limited

For General Information, page-2412

  1. 2,940 Posts.
    lightbulb Created with Sketch. 476
    The science is hard to get one's head around for the average layperson imo -

    CAP 1002 and ATL 1102 are two different therapies for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle loss and premature death. CAP 1002 is a cell therapy that uses donor heart cells to reduce inflammation and muscle degeneration12. ATL 1102 is an antisense inhibitor that targets a protein involved in the fibrotic process in DMD

    Bottom line, I guess it will be a case of which therapy works best and who gets there first with runs on the board!  - as we all know, there are no guarantees of success in the Biotech space with everyone competing to be first past the post - just maybe ATL1102 will deliver the goods this time around for all concerned!

    GLTAH's
    .
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.7¢
Change
0.002(2.35%)
Mkt cap ! $78.43M
Open High Low Value Volume
8.6¢ 8.9¢ 8.5¢ $53.40K 614.3K

Buyers (Bids)

No. Vol. Price($)
1 49999 8.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 67263 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.